SAN FRANCISCO — More patients with dry age-related macular degeneration treated with risuteganib, a small synthetic peptide that regulates select integrin functions involved in the pathogenesis of the disease, experienced an eight or more letter gain in best corrected visual acuity 12 weeks after treatment compared with a sham group, according to a speaker here.
“In phase 2, it hit its primary endpoint with 48% of patients gaining eight letters vs. 7% of a sham group,” David S. Boyer, MD, said at Retina Subspecialty Day at the American Academy of (Read more...)
Uncategorized